Current Report Filing (8-k)
April 21 2017 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
April 18, 2017
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-51652
|
98-0608404
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
51
West 52nd Street, 7th Floor, New York, NY USA 10019
(Address of principal executive offices) (Zip Code)
Registrant's telephone number,
including area code
1-844-689-3939
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On April 18, 2017, Anavex
Life Sciences Corp., a Nevada corporation (the “
Company
”), held a special meeting of stockholders (the “
Meeting
”)
as prescribed in the Proxy Statement filed by the Company with the Securities and Exchange Commission on March 10, 2017. At the
Meeting, five proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:
Proposal No. 1
: The
election of Christopher Missling, Ph.D., Athanasios Skarpelos, Bernd Metzner, Ph.D., Elliot Favus, M.D., Steffen Thomas, Ph.D.,
and Peter Donhauser, D.O. for terms until the next annual meeting of stockholders or until each such director’s successor
shall have been duly elected and qualified
. The stockholders elected each of the six directors by the following votes:
Director
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
Christopher Missling, Ph.D.
|
20,994,287
|
143,387
|
11,605,706
|
Athanasios Skarpelos
|
20,402,917
|
734,757
|
11,605,706
|
Bernd Metzner, Ph.D.
|
20,045,674
|
1,092,000
|
11,605,706
|
Elliot Favus, M.D.
|
20,987,992
|
149,682
|
11,605,706
|
Steffen Thomas, Ph.D.
|
20,423,109
|
714,565
|
11,605,706
|
Peter Donhauser, D.O.
|
20,989,746
|
147,928
|
11,605,706
|
Proposal No. 2:
Regarding a vote to amend the Company’s Articles of Incorporation to authorize up to 10,000,000 shares of preferred stock
of the Company, par value $0.001 per share.
The stockholders did not submit enough affirmative votes to approve the amendment
of the Company’s Articles of Incorporation as set forth in this proposal with respect to authorizing 10,000,000 shares of
preferred stock of the Company as follows:
Votes For
|
18,659,912
|
Votes Against
|
2,218,830
|
Abstentions
|
258,932
|
Broker Non-Votes
|
11,605,706
|
Proposal
No. 3
: The approval of a Shareholder Rights Plan
. The stockholders approved the adoption of a Stockholder Rights
Plan as follows:
Votes For
|
19,895,990
|
Votes Against
|
1,177,192
|
Abstentions
|
64,492
|
Broker Non-Votes
|
11,605,706
|
Proposal No. 4
:
Ratification
of Independent Registered Public Accounting Firm
. The stockholders ratified BDO USA, LLP as the Company’s independent
registered public accounting firm as follows:
Votes For
|
32,456,763
|
Votes Against
|
93,762
|
Abstentions
|
192,855
|
Proposal No. 5
: Approval
of Issuance of Common Stock
. The stockholders approved the issuance of common stock of the Company under the Purchase Agreement
dated October 21, 2015, by and between the Company and Lincoln Park Capital Fund, LLC as follows:
Votes For
|
20,092,854
|
Votes Against
|
786,722
|
Abstentions
|
258,098
|
Broker Non-Votes
|
11,605,706
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ANAVEX LIFE SCIENCES CORP.
|
|
|
|
|
|
/s/ Christopher Missling
|
|
Name: Christopher Missling, PhD
|
|
Title: Chief Executive Officer
|
|
|
Date: April 21, 2017
|
|
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024